证券代码：871970 证券简称：大禹生物 公告编号：2025-046 山西大禹生物工程股份有限公司 2024 年度独立董事述职报告（武晓锋） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人武晓锋，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、勤勉地 履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤其关注 中小投资者的合法权益不受损害。现将本人 2024 年履行独立董事职责情况汇报 如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 除独立董事之外的其他职务，也未在公司主要股东处担任任何职务；没有为公司 或其附属企业提供财务、法律、咨询 ...

证券代码：871970 证券简称：大禹生物 公告编号：2025-044 山西大禹生物工程股份有限公司 2024 年度独立董事述职报告（吴秋生） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人吴秋生，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、勤勉地 履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤其关注 中小投资者的合法权益不受损害。现将本人 2024 年履行独立董事职责情况汇报 如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 除独立董事之外的其他职务，也未在公司主要股东处担任任何职务；没有为公司 或其附属企业提供财务、法律、咨询 ...

山西大禹生物工程股份有限公司 2024 年度独立董事述职报告（宋晓敏） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：871970 证券简称：大禹生物 公告编号：2025-045 本人宋晓敏，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、勤勉地 履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤其关注 中小投资者的合法权益不受损害。现将本人 2024 年履行独立董事职责情况汇报 如下： 一、独立董事独立性情况 因此对 2024 年度任职期间提交董事会审议的各项议案均没有提出异议。 | 独立董事 | 参加董事会情况 | | | 参加股东大会情况 | | | | --- | --- ...

本制度经公司 2025 年 4 月 25 日第四届董事会第二次会议审议通过，表决 结果：同意 7 票，反对 0 票，弃权 0 票；本制度尚需提交股东会审议。 二、 制度的主要内容，分章节列示： 第一章 总则 第一条 为了规范山西大禹生物工程股份有限公司（以下简称"公司"）募 集资金的使用与管理，提高募集资金使用效益，保护投资者的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《北京证券交易所上市公司持 续监管指引第 9 号——募集资金管理》《北京证券交易所股票上市规则》等法律 法规、规范性文件，以及《山西大禹生物工程股份有限公司章程》（以下简称"《公 司章程》"）的规定，结合公司实际情况，制定本制度。 证券代码：871970 证券简称：大禹生物 公告编号：2025-056 山西大禹生物工程股份有限公司募集资金管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 第二条 本制度所称募集资金是指，公司通过向不特定合格投资者发行证券 （包括公开发行股票并在北交所上市、 ...

Financial Performance - Operating revenue for the first quarter reached CNY 29,472,938.03, a 17.42% increase year-on-year[11] - Net profit attributable to shareholders improved by 27.21% to a loss of CNY 3,239,570.36 compared to the same period last year[11] - Total operating revenue for Q1 2025 reached ¥29,472,938.03, a 17.5% increase from ¥25,100,709.69 in Q1 2024[38] - Operating profit for Q1 2025 was -¥3,237,906.01, an improvement from -¥4,450,874.50 in Q1 2024[38] - Net profit for Q1 2025 was -¥3,239,570.36, compared to -¥4,450,874.05 in Q1 2024, indicating a reduction in losses[39] - The total comprehensive loss for Q1 2025 was -¥3,239,570.36, compared to -¥4,450,874.05 in Q1 2024, reflecting an overall improvement[40] Cash Flow - Net cash flow from operating activities surged by 1,764.27% to CNY 12,612,429.32, primarily due to government subsidies received[11][12] - Cash inflow from operating activities totaled CNY 46,146,883.69, an increase from CNY 31,482,031.79 in the previous period, representing a growth of 46.6%[45] - Net cash flow from operating activities was CNY 12,612,429.32, a significant improvement compared to a negative cash flow of CNY -757,836.73 in the prior period[45] - The net increase in cash and cash equivalents was CNY 26,915,069.01, a substantial rise from CNY 1,336,650.48 in the previous period[46] - The ending balance of cash and cash equivalents reached CNY 52,589,902.75, significantly higher than CNY 21,137,550.78 at the end of the previous period[46] Assets and Liabilities - Total assets increased by 8.31% to CNY 426,072,602.07 compared to the end of the previous year[11] - The asset-liability ratio for the consolidated entity rose to 31.91%, compared to 25.43% at the end of the previous year[11] - Total liabilities reached CNY 135,946,360.22, up from CNY 100,018,121.68, indicating a growth of around 35.6%[33] - Current liabilities rose to CNY 95,574,466.26, compared to CNY 77,168,956.05, marking an increase of about 23.8%[32] - Non-current liabilities increased significantly to CNY 40,371,893.96 from CNY 22,849,165.63, reflecting an increase of approximately 76.5%[33] - Owner's equity decreased slightly to CNY 290,126,241.85 from CNY 293,365,812.21, a decline of about 1.0%[33] Shareholder Information - The total number of ordinary shareholders was reported at 5,936 as of the end of the reporting period[18] - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of total shares[20] - The total number of shares held by the top ten shareholders is 70,263,404, accounting for 63.09% of total shares[20] Inventory and Investments - Inventory rose to CNY 23,028,196.73 from CNY 19,147,617.40, representing an increase of about 20.0%[36] - Long-term equity investments increased to CNY 6,100,000.00 from CNY 3,600,000.00, marking an increase of about 69.4%[36] Expenses - Research and development expenses for Q1 2025 were ¥1,818,246.15, down from ¥2,226,327.07 in Q1 2024[41] - Sales expenses decreased to ¥2,877,982.94 in Q1 2025 from ¥3,213,744.05 in Q1 2024[41] - Management expenses for Q1 2025 were ¥4,092,979.85, a decrease from ¥4,935,422.02 in Q1 2024[41] Government Subsidies - The company received government subsidies totaling CNY 1,208,733.36, contributing to non-recurring gains[16]

Financial Performance - In 2024, the company's operating revenue was approximately ¥122.51 million, a decrease of 23.71% compared to ¥160.58 million in 2023[28] - The gross profit margin for 2024 was 24.98%, down from 27.28% in 2023[28] - The net profit attributable to shareholders was approximately -¥23.94 million, representing a significant decline of 1,045.71% compared to -¥2.09 million in 2023[28] - The weighted average return on net assets based on net profit attributable to shareholders was -7.84% in 2024, compared to -0.62% in 2023[28] - The basic earnings per share for 2024 was -0.22, a decrease of 1,000% from -0.02 in 2023[28] - Total assets decreased by 7.16% to 393.38 billion from 423.71 billion at the end of 2023[31] - Total liabilities decreased by 6.00% to 100.02 billion from 106.40 billion at the end of 2023[31] - Net profit attributable to shareholders decreased by 7.55% to 293.37 billion from 317.31 billion at the end of 2023[31] - Revenue for the year was 122.51 million, a slight decrease of 0.01% compared to the preliminary report[33] - Net profit attributable to shareholders was -23.94 million, a decrease of 3.08% from the preliminary report[33] Research and Development - The company obtained five utility model patents in 2024, including a non-contact intelligent defoaming device and a solid powder and water mixing dust purification recovery system[7] - Research and development expenses were ¥8,588,792.17, accounting for 7.01% of total revenue, down 16.29% from the previous year[56] - The company has increased its patent holdings to 38, up from 33 in the previous period, maintaining 14 invention patents[90] - The total number of R&D personnel decreased to 44 from 52, with R&D personnel representing 13.61% of the total workforce[89] - The company is in the pilot stage of developing a high-efficiency single-cell protein strain using methanol as a carbon source, which is expected to enhance product variety and economic benefits[92] - The company has completed the optimization of fermentation feed standards, which is anticipated to improve production processes and bring economic benefits[93] - A new strain of probiotic has been selected to inhibit the production of gas-producing Clostridium, aimed at reducing the incidence of related diseases in livestock, contributing to economic gains[93] - The company is conducting research on the fermentation process of Sichuan pepper seed meal, which is expected to optimize production and enhance product quality, leading to economic benefits[93] - The company has developed a functional probiotic capable of degrading harmful substances in aquaculture water, contributing to a healthier aquatic environment[93] Business Expansion and Strategy - The company established a wholly-owned subsidiary, Shanxi Dayu Animal Husbandry Co., Ltd., and completed the business registration on December 18, 2024[9] - The company established a wholly-owned subsidiary to extend its business into pig farming beyond its main business of feed and feed additives[43] - The company has expanded its foreign sales channels during the reporting period[43] - The company plans to launch four new product categories in the aquaculture sector by 2025, including water purification and ammonia reduction products, to meet the growing demand for enzyme products[104] - The company aims to enhance its sales strategy by focusing on regional feed brands and expanding into poultry and aquaculture markets, with a particular emphasis on differentiated product promotion[113] - The company will extend its industrial chain into pig farming to stabilize sales channels for feed and additives, aiming to create a closed-loop sales model and reduce production costs[111] - The company recognizes the risks posed by price fluctuations in the pig market and the potential impact of African swine fever on its business operations[116] Operational Efficiency - Operating cash flow increased by 139.41% to 18.39 million from 7.68 million in the previous year[32] - The total operating costs decreased by 21.29% to ¥91,912,539.65, reflecting the decline in sales revenue[56] - The company's management expenses increased by 26.36% to ¥24,924,712.00, primarily due to depreciation costs from a new automated production facility[59] - The credit impairment loss surged by 515.07% to ¥3,398,262.74, attributed to increased bad debt provisions amid structural adjustments in the downstream breeding industry[59] - The company will optimize production arrangements and enhance procurement capabilities to lower production costs[108] - The company aims to improve its internal management systems to enhance operational efficiency and risk management[115] Governance and Compliance - The company has established a governance structure to ensure decision-making processes are transparent and protect minority shareholders[120] - The company reported a total of 678,251.50 yuan in litigation as a plaintiff, representing 0.23% of the net assets at the end of the reporting period[124] - The company has no significant related party transactions during the reporting period, ensuring no misuse of funds or assets[127] - The company has a robust governance structure, with independent directors meeting the required independence criteria[190] - The company has established a sound internal control management system, ensuring compliance with laws and regulations, and maintaining operational integrity[183] - The audit committee confirmed that the financial reports accurately reflect the company's performance and financial status, with no significant omissions or misleading statements[185] - The company held five board meetings during the reporting period, addressing significant matters including the annual financial report and budget for 2024[178] Shareholder Information - The actual controllers of the company hold 49.94% of the total shares, which may influence major decisions and potentially affect minority shareholders' interests[120] - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[138] - The total number of shares held by the top ten shareholders is 71,921,289, accounting for 64.57% of the total shares[138] - The company has a total of 5,379 shareholders as of the end of the reporting period[136] - The company has not proposed any cash dividend distribution plan during the reporting period despite having positive undistributed profits[152] - The cash dividend policy is compliant with the company's articles of association and has clear standards and procedures[152] - The company has ensured that minority shareholders have the opportunity to express their opinions and that their rights are protected[152] Employee Information - The company had a total of 334 employees at the end of the reporting period, down from 382 at the beginning, reflecting a net decrease of 48 employees[163] - The company implements a comprehensive labor contract system, ensuring compliance with the Labor Law of the People's Republic of China and local regulations, providing salaries, allowances, and bonuses to all employees[165] - Employee training programs are prioritized, including onboarding, skills training, and management skills training, aimed at enhancing overall employee capabilities[165] - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 2.363 million[162] Financial Obligations - The total loan amount provided by various banks is 82,600,000.00, with an average interest rate of approximately 3.60%[150] - The company has secured a mortgage loan of 5,000,000.00 from China Post Bank with a term starting in January 2024 and ending in January 2025 at an interest rate of 3.60%[150] - A loan of 25,000,000.00 was obtained from a commercial bank, with a term from May 2024 to May 2025 at an interest rate of 3.65%[150] - The company has also secured a guarantee loan of 3,000,000.00 from Shanghai Pudong Development Bank, with a term from November 2024 to November 2025 at an interest rate of 3.30%[151]

证券代码：871970 证券简称:大禹生物 公告编号：2025-032 山西大禹生物工程股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 3 个有成交的交易日（2025 年 4 月 3 日至 2025 年 4 月 8 日）以内收盘价 涨幅偏离值累计达到 44.64%，根据《北京证券交易所交易规则（试行）》的有关规定，属于 股票交易异常波动情形。 二、公司关注并核实的相关情况 1、 核实对象： 公司控股股东、实际控制人及一致行动人、持股 5%以上股东，在任的董事、监事及高 级管理人员。 2、 核实方式： 3、 核实结论： 前期公告的事项不存在需要更正、补充之处,未发现可能或已经对本公司股票交易价格 产生较大影响的媒体报道或市场传闻，不涉及热点概念事项；近期公司经营情况及内外部经 营环境未发生重大变化；公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项；不存在其他可能对股价产生较大影响的 ...

证券代码：871970 证券简称:大禹生物 公告编号：2025-031 2、 核实方式： 电话询问、口头询问、微信询问等方式。 3、 核实结论： 前期公告的事项不存在需要更正、补充之处,未发现可能或已经对本公司股票交易价格 产生较大影响的媒体报道或市场传闻，不涉及热点概念事项；近期公司经营情况及内外部经 营环境未发生重大变化；公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项；不存在其他可能对股价产生较大影响的重大事件。 山西大禹生物工程股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 3 个有成交的交易日（2025 年 3 月 25 日至 2025 年 3 月 27 日）以内收盘 价涨幅偏离值累计达到 42.20%，根据《北京证券交易所交易规则（试行）》的有关规定，属 于股票交易异常波动情形。 二、公司关注并核实的相关情况 1、 核实对象： 公司控股股东、实际控制人及一致行动人、持 ...

大禹生物（871970）今日上涨21.47%，全天换手率30.06%，成交额1.78亿元，振幅32.91%。龙虎榜 数据显示，营业部席位合计净卖出952.40万元。 北交所公开信息显示，当日该股因日涨跌幅达到21.47%、日价格振幅达32.91%上榜，营业部席位 合计净卖出952.40万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5749.90万元，其中，买入成交额为 2398.75万元，卖出成交额为3351.15万元，合计净卖出952.40万元。 具体来看，今日上榜营业部中，第一大买入营业部为国金证券股份有限公司南京双龙大道证券营业 部，买入金额为606.38万元，第一大卖出营业部为国投证券股份有限公司湖北分公司，卖出金额为 1069.49万元。（数据宝） 大禹生物3月26日交易公开信息 大禹生物龙虎榜：营业部净卖出952.40万元 （文章来源：证券时报网） | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国金证券股份有限公司南京双龙大道证券营业部 | 606.38 | 0.00 | | 买二 ...

证券代码：871970 证券简称：大禹生物 公告编号：2025-030 山西大禹生物工程股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一） 股东因以下原因披露减持计划实施结果： √减持计划实施完毕 □减持时间区间届满 | 股东名称 | 已减持数量 | 已减持 | 减持 | 减持 | | 减持价格 | 已减持总金额 | 减持计划完 | | 当前持股数量 | 当前持股比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | （股） | 比例 | 方式 | 期间 | | 区间 | （元） | 成情况 | | （股） | 例 | | 厚扬天灏 | 2,219,960 | 1.9935% | 集 中 竞 | 2025 年 | 1 | 5.62-6.67 | 12,979,204.35 | | 是 | 5,764,040 | 5.1760% | | | | ...